Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. - sprookjes - yvandenbroek - TriplyDB

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

http://www.wikidata.org/entity/Q34590731

about

Anti-angiogenic therapies for metastatic colorectal cancer NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives Current targeted therapies in the treatment of advanced colorectal cancer: a review Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy Pharmacologic resistance in colorectal cancer: a review Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis A Systematic Review and Network Meta-Analysis of Biologic Agents in the First Line Setting for Advanced Colorectal Cancer Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Inflammation-based factors and prognosis in patients with colorectal cancer Anti-angiogenic agents in metastatic colorectal cancer Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups Management of colorectal cancer The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives Molecularly targeted drugs for metastatic colorectal cancer Role of surgery in colorectal cancer liver metastases Value of bevacizumab in treatment of colorectal cancer: A meta-analysis Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis Anti-vascular endothelial growth factor therapy in breast cancer Effectiveness and safety of s-1-based therapy compared with 5-Fluorouracil-based therapy for advanced colorectal cancer: a meta-analysis Angiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage?Review of systemic therapies for locally advanced and metastatic rectal cancer Management of locally advanced and metastatic colon cancer in elderly patients How to select the optimal treatment for first line metastatic colorectal cancer Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis Surgery for colorectal liver metastases: The evolution of determining prognosis Regorafenib in metastatic colorectal cancer.Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer

P2860

Q24241813-B753C206-E8D6-430F-8674-4E2431658B7B Q24298410-30ED3D62-50CA-412D-B9F4-38014CA853BF Q24657761-82B309B8-177C-4972-BB76-5ECDD21E9C0D Q26738801-FCAC1E18-268C-4A2D-B805-9F6DC69B5DEC Q26740067-B77211CD-020E-42B8-8A0B-F3FC5D7219F3 Q26740812-005D7128-B08C-4F3C-9FD4-01A1DBB8C507 Q26746067-D395FC90-C143-4BE7-BE51-7E466BEA55EB Q26748924-B55F53F9-45D1-4C11-85FE-A7C1F7DF1C4B Q26751344-0D07AC02-C8FF-4B02-8CC9-B1EB88018992 Q26768402-6943C456-997D-4DC2-99E6-2202ACFF2C4A Q26769850-9FF96B95-0407-40B9-AEEC-597859B97791 Q26774605-9371544B-9462-4F61-9E56-E5725E84378C Q26775522-2AD78818-6CCF-4A81-A8CB-3E0F691AF926 Q26775949-A6CCE388-2EA4-4E79-9C92-15E386416992 Q26777704-2E23AE9D-23AA-4D76-B877-ECB5B2700D14 Q26782245-253A57DF-86D4-4295-8844-CFA5C4EC9B59 Q26786618-4CF3E278-81F1-45C6-9553-55A07F4872B3 Q26797425-0164DB1A-A679-4228-81AD-92321CB41BE3 Q26801911-5BF27383-9E5E-48B4-96FF-9D0DF042F446 Q26822395-691C5A59-66B7-4214-B52E-55883FBC88B5 Q26823550-7D64262A-7C08-4C0E-8B4F-FA193439413F Q26824086-34913C84-943A-4EBD-B719-DFD1F8B1C176 Q26826817-F99871D9-34D4-4239-A03B-54AA4C8B8B98 Q26828735-6A174630-62EF-4365-BB3B-E736E8724335 Q26830444-8518C2D6-7194-4332-8EBE-41DDAC0C93E0 Q26849789-3CA59EA6-4D34-4CA4-A8D2-9344759BFBC4 Q26853604-D9533162-3B65-4C0B-A460-5B3AA2F15898 Q26865057-CBB2D082-0F04-42C1-A0B4-B732FBC77FB6 Q26999473-9C8CF36A-86BF-412C-A59C-C6C5520D6420 Q27000790-2AE8E02D-3D67-4ADA-9716-6A6B053749D8 Q27002538-F81E94FB-8F09-4D86-9356-322D20A3D69A Q27021105-73F1FC52-2FE7-4BB4-B6AF-184CDF1ADDBF Q27026129-FD689AFA-9F9B-41A7-A20D-8769C55960BC Q27026516-3EDED253-F2E8-4C2C-ACA0-06642D47C2F4 Q27026936-EEB2DF77-4B91-490E-BE21-4A01E416C32F Q27694490-ECE2779F-6AB7-4BF8-B8C0-E23240F158BA Q27852864-1F056F73-A1EF-452B-AB3B-1B9D11428346 Q27853168-7DC20BD8-2F7E-4F12-A979-22DAF164F36D Q27853306-33C5A061-2C29-4867-B04A-3E6D96B1CB86 Q28068654-669307FA-53A9-4903-BD9B-5AF2F85F7152

P2860

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

http://www.wikidata.org/entity/Q34590731

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Bevacizumab in combination wit ...... a randomized phase III study.

@en

Bevacizumab in combination wit ...... a randomized phase III study.

@nl

type

label

Bevacizumab in combination wit ...... a randomized phase III study.

@en

Bevacizumab in combination wit ...... a randomized phase III study.

@nl

prefLabel

Bevacizumab in combination wit ...... a randomized phase III study.

@en

Bevacizumab in combination wit ...... a randomized phase III study.

@nl

P1433

Q34590731-9F09EF0F-86B2-424C-97AC-26D1CC2829B6

P1476

Q34590731-E9B9A791-014B-4A13-B36D-9351FCAE7FA3

P2093

Q34590731-0A244750-C01E-41ED-9F7E-37761037A2F5

Q34590731-1032C79B-C47A-43CB-AB20-737CBD757125

Q34590731-1448B12F-63F4-48AD-B81C-534144076E9F

Q34590731-434C35F3-23A6-4554-B6EF-88A62FCA65D1

Q34590731-4AC42614-2A39-4C53-8F70-838AC665B42A

Q34590731-6C9E14FF-42F4-4F2A-9012-2964D0EC5B51

Q34590731-B78D1AE2-3B63-4008-A855-ACF5C7F7DBC5

Q34590731-BAA9CCCD-2DAE-4671-9865-A94177986387

Q34590731-C387E3F9-A65F-4CF9-933F-BCD6A3927C4F

Q34590731-CCFDB80E-022E-449D-A6C5-31C9B9CB7CE5

P304

Q34590731-AE5C0106-5CFA-487D-B5E5-384E327654CA

P31

Q34590731-F3738D1C-F008-4946-8B92-A6B461E5E64C

P356

Q34590731-09AD1FDC-7CD1-4726-8465-BD19B5FAAF42

P407

Q34590731-C5B07914-785A-4173-B2D1-2F534EE1C2D3

P433

Q34590731-4F72ACCA-AA94-4977-BAAE-DD302702980D

P478

Q34590731-9AF3E135-C965-4249-A70A-CA2C25856978

P50

Q34590731-5510EFF3-6FBE-4762-89D3-C4AC0D4305F8

Q34590731-FEC9D837-C220-4A34-86CC-871D160A957E

P577

Q34590731-345D1C58-6BB0-4918-8F68-7CD32DA1BB41

P698

Q34590731-E696D883-AE29-4377-89D1-4850EA6654CF

P921

Q34590731-2072CE4C-2DCF-4278-8387-ACFC4EA2B87A

Q34590731-79D99A73-B664-4B47-AAF1-F077CE1897BB

Q34590731-C5E1CBEE-8E2F-47BA-8F4E-23CA8844D8FF

P356

JCO.2007.14.9930

P1433

Journal of Clinical Oncology

P1476

Bevacizumab in combination wit ...... : a randomized phase III study

@en

P2093

Arie Figer

http://www.w3.org/2001/XMLSchema#string

Felix Couture

http://www.w3.org/2001/XMLSchema#string

Fernando Rivera

http://www.w3.org/2001/XMLSchema#string

Florin Sirzén

http://www.w3.org/2001/XMLSchema#string

Jim Cassidy

http://www.w3.org/2001/XMLSchema#string

Mikhail Lichinitser

http://www.w3.org/2001/XMLSchema#string

Ralph Wong

http://www.w3.org/2001/XMLSchema#string

Sheryl Koski

http://www.w3.org/2001/XMLSchema#string

Stephen Clarke

http://www.w3.org/2001/XMLSchema#string

Tsai-Shen Yang

http://www.w3.org/2001/XMLSchema#string

P304

2013-2019

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.14.9930

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Leonard B. Saltz

Eduardo Díaz-Rubio

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18421054

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer